Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors
SJATRT - Phase 2 Study Of Alisertib As A Single Agent In Recurrent Or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) And Extra-Cns Malignant Rhabdoid Tumors (MRT) And In Combination Therapy In Newly Diagnosed At/Rt
-
Clinical Trial Information
Trial Contact: Spinelli, Jennifer; Parker, Melanie
Trial Phone: 321.841.5357 ; 321-841-7561
-
IRB No: 15.118.09
Protocol Abbrev: SJATRT
Principal Investigator: Amy A Smith, MD
Phase: Drug: Phase II
Age Group: Pediatric
Secondary Protocol No: SJATRT
Treatment: Drug: alisertib Procedure: Surgical Resection Drug: methotrexate Drug: cisplatin Drug:carboplatin Drug: cyclophosphamide Drug: etoposide Drug: topotecan Drug: vincristine Radiation: Radiation therapy Drug: cytoxan
Therapies Involved: Medication; Chemotherapy
ClinicalTrials.gov ID: NCT02114229
-
Objective
To estimate the sustained objective response rate and disease stabilization in pediatric patients with recurrent or progressive AT/RT (atypical teratoid rhabdoid tumor in the CNS) (Stratum A1) treated with alisertib and to determine if the response is sufficient to merit continued investigation of alisertib in this population.
• To estimate the sustained objective response rate and disease stabilization in pediatric patients with recurrent or progressive extra-CNS MRT (malignant rhabdoid tumor outside the CNS) (Stratum A2) treated with alisertib and to determine if the response is sufficient to merit continued investigation of alisertib in this population.
• To estimate the 3-year PFS rate of patients with newly diagnosed AT/RT who are younger than 36 months of age at diagnosis with no metastatic disease (Stratum B1) treated with alisertib in sequence with induction and consolidation chemotherapy and radiation therapy (depending on age) and to determine if the rates are sufficient to merit continued investigation of alisertib in this population.
• To estimate the 1-year PFS rate of patients with newly diagnosed AT/RT who are younger than 36 months of age at diagnosis, with metastatic disease (Stratum B2) treated with alisertib in sequence with induction and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population.
• To estimate the 3-year PFS rate of patients with newly diagnosed AT/RT who are 3 years of age or greater at diagnosis with no metastatic disease and gross total resection or near total resection (Stratum C1) treated with alisertib in sequence with radiation therapy and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population.
• To estimate the 1-year PFS rate of patients with newly diagnosed AT/RT who are 3 years of age or greater at diagnosis with metastatic or residual disease (Stratum C2) treated with alisertib in sequence with radiation therapy and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population.
• To characterize the pharmacokinetics and pharmacodynamics of alisertib in pediatric patients and to relate drug disposition to toxicity -
Key Eligibility
Ages Eligible for Study: up to 21 Years Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
